Evidence map›Paper›PMID 42517628›Full record

ArticleMicrobiology spectrum2026

No phenotypic resistance observed for most group-3 and -4 variants in

Faridath Massou, Klaas Dewaele, Anderson Gnamy, Ramata Balde, Wim Mulders, Conor J Mehan, Bouke C de Jong, Dissou Affolabi, Oren Tzfadia, Leen Rigouts

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbiology spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Faridath MassouSupranational Reference Laboratory of Tuberculosis, Cotonou, Bénin.ORCID 0000-0002-3045-3778
Klaas DewaeleMycobacteriology unit, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.ORCID 0000-0002-7029-2470
Anderson GnamySupranational Reference Laboratory of Tuberculosis, Cotonou, Bénin.
Ramata BaldeMycobacteriology unit, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
Wim MuldersMycobacteriology unit, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.ORCID 0000-0002-9566-3653
Conor J MehanMycobacteriology unit, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
Bouke C de JongMycobacteriology unit, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.ORCID 0000-0002-1017-4675
Dissou AffolabiSupranational Reference Laboratory of Tuberculosis, Cotonou, Bénin.
Oren TzfadiaMycobacteriology unit, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.ORCID 0000-0002-7096-8063
Leen RigoutsMycobacteriology unit, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.ORCID 0000-0003-3301-9480

Funding

Belgisch Ontwikkelingsagentschap 911063/70/150European and Developing Countries Clinical Trials Partnership DRIA2014-326
6 · The paper itself

Abstract

The interpretation of genetic variants' association (or not) with phenotypic resistance to newly introduced and repurposed antituberculosis drugs remains challenging, as many mutations detected by whole-genome sequencing (WGS) are classified as of uncertain significance (group 3) or not associated with resistance-interim (group 4) by the World Health Organization (WHO) mutation catalog v2. We evaluated the phenotypic impact of such variants on minimum inhibitory concentrations (MICs) for bedaquiline (BDQ), clofazimine (CFZ), delamanid (DLM), and pretomanid (PA) in

Indexed as

Antitubercular AgentsMycobacterium tuberculosisAfrica, CentralAfrica, WesternClofazimineDiarylquinolinesDrug Resistance, BacterialHumansMicrobial Sensitivity TestsMutationNitroimidazolesOxazolesPhenotypeWhole Genome SequencingAntitubercular AgentsbedaquilineClofazimineDiarylquinolinesNitroimidazolesOPC-67683Oxazolespretomanidminimum inhibitory concentrationMycobacterium tuberculosiswhole-genome sequencing

Identifiers

PMID42517628
PMCPMC13532243

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.